Bone Remodeling Dynamics in Osteoporotic Conditions

Bone remodelling is a finely tuned process in which osteoclasts resorb aged or damaged bone and osteoblasts subsequently form new matrix. In osteoporosis, this balance shifts towards excessive resorption, leading to reduced bone mass, microarchitectural deterioration and increased fracture risk. Ageing, hormonal changes, chronic inflammation and oxidative stress all contribute to altered signalling through pathways such as RANK/RANKL/OPG and Wnt/β-catenin, as well as epigenetic modifications including histone methylation. Mesenchymal stem cells in the marrow niche may lose osteogenic potential under senescent or diabetic conditions, further compounding bone loss. Globally, osteoporosis represents a major public health challenge, driving efforts to develop targeted therapies that restore remodelling equilibrium, reinforce bone strength and reduce the burden of low-trauma fractures.

Research from Nature Portfolio

Work on α-ketoglutarate has revealed its capacity to rejuvenate ageing bone marrow mesenchymal stem cells by reducing repressive histone methylation marks, thereby enhancing osteogenic gene expression and increasing bone mass in aged rodent models. Separately, studies of a natural polysaccharide have demonstrated dual action in promoting osteoblast differentiation and inhibiting RANKL-driven osteoclastogenesis via activation of Wnt/β-catenin signalling, resulting in improved bone density and microarchitecture in ovariectomy-induced osteoporosis.

Bone Remodeling Dynamics in Osteoporotic Conditions publication trend

The graph below shows the total number of articles in bone remodeling dynamics in osteoporotic conditions across all publications each year (not limited to Nature Index journals).

Technical terms

Bone remodelling: The continuous process of bone resorption by osteoclasts and formation by osteoblasts that maintains skeletal integrity.

Osteoclast: A multinucleated cell that degrades bone matrix through secretion of acid and proteolytic enzymes.

Osteoblast: A bone-forming cell that synthesises collagen and regulates mineral deposition.

Mesenchymal stem cell (MSC): A progenitor cell in the bone marrow capable of differentiating into osteoblasts, chondrocytes and adipocytes.

Receptor activator of NF-κB ligand (RANKL): A cytokine essential for osteoclast differentiation and activation.

Ferroptosis: An iron-dependent form of regulated cell death characterised by lipid peroxidation, implicated in impaired osteogenesis.

Wnt/β-catenin pathway: A signalling cascade that promotes osteoblast proliferation, differentiation and bone matrix synthesis.

References

1. A DNA tetrahedron-based ferroptosis-suppressing nanoparticle: superior delivery of curcumin and alleviation of diabetic osteoporosis. Bone Research (2024).
2. Osteoporotic osseointegration: therapeutic hallmarks and engineering strategies. Theranostics (2024).
3. Smart osteoclasts targeted nanomedicine based on amorphous CaCO3 for effective osteoporosis reversal. Journal of Nanobiotechnology (2024).
4. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nature Communications (2020).
5. Polygonatum sibiricum polysaccharide inhibits osteoporosis by promoting osteoblast formation and blocking osteoclastogenesis through Wnt/β-catenin signalling pathway. Scientific Reports (2016).